Adalimumab exhibits superiority over etanercept in terms of a numerically higher response rate and equivalent adverse events: A real ‐world finding

ConclusionADA shows superiority over ETN in terms of a numerically greater response rate and equivalent adverse events.

Source: Immunity, Inflammation and Disease - February 1, 2024 Category: Allergy & Immunology Authors: Zhe Yu, Ling Gao, Yinshan Zang, Lu Cheng, Wenjia Gao, Yan Xu Tags: ORIGINAL ARTICLE Source Type: research